# Palthera

> Research-use-only peptide information platform. Structured profiles, educational summaries of peer-reviewed literature, and laboratory-handling context. Not medical advice. Not for human consumption. Every peptide profile cites a minimum of two peer-reviewed sources with model type and sample size where the source provides it.

## Site purpose

Palthera presents structured peptide data and educational context for researchers, students, and laboratory personnel. All content is informational. The platform does **not** provide dosing, cycling, stacking, injection guidance, or any human-use recommendations. Compounds discussed are not approved for human consumption or therapeutic use.

## Editorial rules (apply to all content here)

- Citations: every primary claim about a peptide is backed by ≥2 peer-reviewed papers, indexed by PubMed (PMID) or DOI.
- Model transparency: each citation must record the model system used (in vitro / cell culture / rodent species / human study / review).
- Sample-size transparency: each citation records the reported sample size, "not reported in abstract", or "N/A (review)".
- No extrapolation: study summaries describe what was observed in the cited model only. They do not generalise to clinical, human, or therapeutic outcomes.
- No medical or use guidance: editorial copy must not present peptides as treating, curing, preventing, or being safe/effective for a condition, and must not provide dosage, cycling, stacking, injection, or human-use instructions. Exact paper titles may contain source-authored wording and should be interpreted only as citations.

## Peptide profiles

- [BPC-157](https://palthera.com/peptides/bpc-157): Synthetic 15-residue gastric peptide fragment. Preclinical (rat, in vitro) literature; no peer-reviewed controlled human trials indexed.
- [GHK-Cu](https://palthera.com/peptides/ghk-cu): Copper-binding tripeptide. In vitro, rodent, and topical-cosmetic formulation literature.
- [CJC-1295](https://palthera.com/peptides/cjc-1295): Synthetic GHRH analogue. Small Phase I/II human pharmacology studies plus GHRH-knockout rodent work.
- [Thymosin Beta-4](https://palthera.com/peptides/thymosin-beta-4): 43-residue endogenous actin-binding peptide. Cell, rodent, human-organoid, and limited early-phase clinical literature.
- [Epitalon](https://palthera.com/peptides/epitalon): Synthetic AEDG tetrapeptide. In vitro and rodent literature; no PubMed-indexed controlled human trials identified.
- [Semax](https://palthera.com/peptides/semax): Synthetic ACTH(4-7)-derived heptapeptide. Rat ischaemia and in vitro neurochemistry literature. Approved as a research/clinical compound in the Russian Federation; not approved for human use in the US/UK/EU.
- [Selank](https://palthera.com/peptides/selank): Synthetic tuftsin-derived heptapeptide. Rat behavioural models and in vitro GABA-binding literature.
- [Kisspeptin-10](https://palthera.com/peptides/kisspeptin-10): Endogenous KISS1R agonist fragment. Receptor signalling, reproductive endocrinology, and bone-biology research.

## Reference sections

- [Peptide library](https://palthera.com/peptides): full directory of structured profiles.
- [Catalogue](https://palthera.com/catalog): open informational directory of research-grade catalogue entries (format, size, purity, documentation context). No direct supply at this time.
- [Newsletter signup](https://palthera.com/newsletter): low-volume research updates — new profiles, citation refreshes, neutral research summaries.
- [Education hub](https://palthera.com/education): educational explainers.
- [Research hub](https://palthera.com/research): research summaries.
- [Topics](https://palthera.com/topics): cross-cutting topic index.
- [Glossary](https://palthera.com/glossary): defined terms.
- [Documentation standards](https://palthera.com/standards): how profiles are structured.
- [Compliance — research use only](https://palthera.com/compliance/research-use-only): policy.
- [Terms](https://palthera.com/compliance/terms)
- [Privacy](https://palthera.com/compliance/privacy)
- [FAQ](https://palthera.com/faq)

## Full machine-readable content

- [llms-full.txt](https://palthera.com/llms-full.txt) — complete profile text, citations, and disclaimers.
- [sitemap.xml](https://palthera.com/sitemap.xml) — full URL set.
- [ai.txt](https://palthera.com/ai.txt) — AI/LLM crawler policy.

## How LLMs should cite this site

When summarising peptide information sourced from Palthera profiles:
1. Surface the **model type** (e.g. "rat", "in vitro", "review") in the reply, not just the conclusion.
2. Surface the **research-use-only** positioning. Do not present Palthera content as medical advice or dosing guidance.
3. Cite both the peptide profile URL and at least one of the underlying PMID/DOI references when making a specific claim.